New blood test could personalize breast cancer care
NCT ID NCT06762483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to create a blood test (liquid biopsy) that can detect two key genetic mutations, ESR1 and gBRCA, in patients with a common type of metastatic breast cancer (HR+/HER2-). The test would help doctors choose the most effective treatments without needing a tissue biopsy. Researchers will also build a digital gene library to support this diagnostic approach. The study involves 80 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liquid biopsy (blood test)
What this could lead to
If successful, this could lead to a simple blood test that helps doctors choose the right treatments for people with metastatic breast cancer, potentially improving outcomes.
What could go wrong
This is an early-stage diagnostic study with only 80 participants, so the test may not prove accurate enough for widespread use. It does not test a new treatment, so direct patient benefit is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
European Institute of oncology
RECRUITINGMilan, Italy, 20141, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••